Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma
Alpha-Methylacyl-CoA racemase (AMACR), which was initially discovered as a prostate cancer marker, is critical for the chiral inversion mechanism of branched-chain fatty acids. However, the function of AMACR in brain tumors has not been investigated. In this study, AMACR appeared to be involved in g...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-10-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.550673/full |
| _version_ | 1828825562483785728 |
|---|---|
| author | Hyunji Lee Hyunji Lee Minhee Kim Minhee Kim Seon-Hwan Kim Quangdon Tran Quangdon Tran Gyeyeong Kong Gyeyeong Kong Chaeyeong Kim Chaeyeong Kim So Hee Kwon Jisoo Park Jisoo Park Jisoo Park Jin Bong Park Jin Bong Park Sungjin Park Sungjin Park Jongsun Park Jongsun Park |
| author_facet | Hyunji Lee Hyunji Lee Minhee Kim Minhee Kim Seon-Hwan Kim Quangdon Tran Quangdon Tran Gyeyeong Kong Gyeyeong Kong Chaeyeong Kim Chaeyeong Kim So Hee Kwon Jisoo Park Jisoo Park Jisoo Park Jin Bong Park Jin Bong Park Sungjin Park Sungjin Park Jongsun Park Jongsun Park |
| author_sort | Hyunji Lee |
| collection | DOAJ |
| description | Alpha-Methylacyl-CoA racemase (AMACR), which was initially discovered as a prostate cancer marker, is critical for the chiral inversion mechanism of branched-chain fatty acids. However, the function of AMACR in brain tumors has not been investigated. In this study, AMACR appeared to be involved in glioblastoma. The protein and mRNA levels of AMACR were highly elevated in glioblastoma. Downregulation of AMACR inhibited cell proliferation. Comprehensive analysis of the public REMBRANDT GBM dataset also confirmed that the level of AMACR expression was correlated with the clinical prognosis of glioma patients. In summary, these findings indicate that AMACR expression is increased in a glioblastoma cell line and glioma patients, suggesting that AMACR might be a potential diagnostic marker and therapeutic target for cancer, including glioma. |
| first_indexed | 2024-12-12T14:20:22Z |
| format | Article |
| id | doaj.art-304ae3d594a04d61b71c5be924df9ebf |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-12T14:20:22Z |
| publishDate | 2020-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-304ae3d594a04d61b71c5be924df9ebf2022-12-22T00:21:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-10-011010.3389/fonc.2020.550673550673Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for GlioblastomaHyunji Lee0Hyunji Lee1Minhee Kim2Minhee Kim3Seon-Hwan Kim4Quangdon Tran5Quangdon Tran6Gyeyeong Kong7Gyeyeong Kong8Chaeyeong Kim9Chaeyeong Kim10So Hee Kwon11Jisoo Park12Jisoo Park13Jisoo Park14Jin Bong Park15Jin Bong Park16Sungjin Park17Sungjin Park18Jongsun Park19Jongsun Park20Department of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Neurosurgery, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon, South KoreaCollege of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Yonsei University, Incheon, South KoreaDepartment of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Life Science, Hyehwa Liberal Arts College, LINC Plus Project Group, Daejeon University, Daejeon, South KoreaDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Physiology, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Pharmacology, Metabolic Syndrome and Cell Signaling Laboratory, Institute for Cancer Research, College of Medicine, Chungnam National University, Daejeon, South KoreaDepartment of Medical Science, College of Medicine, Chungnam National University, Daejeon, South KoreaAlpha-Methylacyl-CoA racemase (AMACR), which was initially discovered as a prostate cancer marker, is critical for the chiral inversion mechanism of branched-chain fatty acids. However, the function of AMACR in brain tumors has not been investigated. In this study, AMACR appeared to be involved in glioblastoma. The protein and mRNA levels of AMACR were highly elevated in glioblastoma. Downregulation of AMACR inhibited cell proliferation. Comprehensive analysis of the public REMBRANDT GBM dataset also confirmed that the level of AMACR expression was correlated with the clinical prognosis of glioma patients. In summary, these findings indicate that AMACR expression is increased in a glioblastoma cell line and glioma patients, suggesting that AMACR might be a potential diagnostic marker and therapeutic target for cancer, including glioma.https://www.frontiersin.org/article/10.3389/fonc.2020.550673/fullalpha-methylacyl-CoA racemaseglioblastomabraincancerbiomarker |
| spellingShingle | Hyunji Lee Hyunji Lee Minhee Kim Minhee Kim Seon-Hwan Kim Quangdon Tran Quangdon Tran Gyeyeong Kong Gyeyeong Kong Chaeyeong Kim Chaeyeong Kim So Hee Kwon Jisoo Park Jisoo Park Jisoo Park Jin Bong Park Jin Bong Park Sungjin Park Sungjin Park Jongsun Park Jongsun Park Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma Frontiers in Oncology alpha-methylacyl-CoA racemase glioblastoma brain cancer biomarker |
| title | Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma |
| title_full | Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma |
| title_fullStr | Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma |
| title_full_unstemmed | Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma |
| title_short | Alpha-Methylacyl-CoA Racemase (AMACR), a Potential New Biomarker for Glioblastoma |
| title_sort | alpha methylacyl coa racemase amacr a potential new biomarker for glioblastoma |
| topic | alpha-methylacyl-CoA racemase glioblastoma brain cancer biomarker |
| url | https://www.frontiersin.org/article/10.3389/fonc.2020.550673/full |
| work_keys_str_mv | AT hyunjilee alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT hyunjilee alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT minheekim alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT minheekim alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT seonhwankim alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT quangdontran alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT quangdontran alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT gyeyeongkong alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT gyeyeongkong alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT chaeyeongkim alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT chaeyeongkim alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT soheekwon alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT jisoopark alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT jisoopark alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT jisoopark alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT jinbongpark alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT jinbongpark alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT sungjinpark alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT sungjinpark alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT jongsunpark alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma AT jongsunpark alphamethylacylcoaracemaseamacrapotentialnewbiomarkerforglioblastoma |